DS 2969

Drug Profile

DS 2969

Alternative Names: DS2969

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Antidiarrhoeals
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Clostridium-difficile-infections

Most Recent Events

  • 25 Oct 2017 Adverse events, pharmacokinetics and antimicrobial data from a phase I trial in Healthy volunteers presented at the Infectious Disease Week-2017 (IDW-2017)
  • 18 May 2017 DS 2969 is available for licensing in USA as of 18 May 2017. http://www.daiichisankyo.com/ (Daiichi Sankyo pipeline, May 2017)
  • 01 Jan 2016 Phase-I clinical trials in Clostridium difficile infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top